Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 2

Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea

Narrows Institute for Biomedical Research · with Sun Pharmaceutical Industries Limited · NCT06952517

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 2
Target enrollment
20
US sites recruiting
1
Study start
March 14, 2025
Record last updated
May 6, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.

Being studied: Clascoterone Cream 1%

Conditions: Papular-pustular Rosacea; Papulopustular Rosacea (PPR); Papulopustular Rosacea

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Men and women ages 18+.
  • Diagnosis of rosacea type 2 (papulopustular).
  • Available and willing to comply with study instructions and attend all study visits.
  • Able and willing to provide written and verbal informed consent.
  • Subject has used the same type and brand of make-up, other facial products, and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at least one month prior to the baseline visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study.

Exclusion Criteria

  • Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topical or systemic therapy.
  • Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
  • Pregnant, lactating, or is planning to become pregnant during the study.
  • Subject is currently enrolled in an investigational drug or device study.
  • Subject has received an investigational drug or has been treated with an investigational device within 30 days prior to the initiation of treatment (baseline).
  • Study participant has facial hair that could interfere with the study assessments in the opinion of the investigator.
  • Study participant is unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function.
  • Subject has known hypersensitivity or previous allergic reaction to any of the active or inactive components of the test articles.
  • Subject has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the trial.

Recruiting US locations

  • New York Harbor VA Brooklyn Campus

    Brooklyn, NY 11209

    Site contact: Kayla Zafar, BA · 718-836-6600 · kayla.zafar@va.gov

Study contacts (from the official record)

  • Kayla N Zafar, BA · 718-836-6600 · kayla.zafar@va.gov
All dermatology studies in New York →
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in… (NCT06952517) | Bored Studies